SCHEMBL5954790

SCHEMBL5954790

COO[C@]1(OC)[C@H](O)[C@@H](CO)O[C@]1(n1cc(C)c(N)nc1=O)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5031652 0.95
SCHEMBL6756344 0.82 RNASE1 (0.37)
SCHEMBL5954363 0.81 TK2 (0.33)
SCHEMBL9083312 0.80 PDE3A (0.39)
SCHEMBL5034927 0.79 ABL1 (0.37)
SCHEMBL6382374 0.77 SLC28A1 (0.35)
SCHEMBL1706308 0.77 RNASE1 (0.39)
SCHEMBL6065319 0.76 LMNA (0.32)
SCHEMBL7908351 0.75 TK2 (0.35)
SCHEMBL10381694 0.73 ABL1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611249-A4 OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA ISIS PHARMACEUTICALS INC (US) 2006-06-28 EP disclosed
EP-1611249-A1 OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA ISIS PHARMACEUTICALS, INC. (US) 2006-01-04 EP disclosed
EP-1442046-A4 MAMMALIAN C-TYPE LECTINS IMMUNEX CORP (US) 2005-08-31 EP disclosed
WO-2004097049-A1 OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA ISIS PHARMACEUTICALS, INC. (US) 2004-11-11 WO disclosed
EP-1442046-A2 MAMMALIAN C-TYPE LECTINS Immunex CorporatioN (US) 2004-08-04 EP disclosed
EP-1064402-A4 ANTISENSE MODULATION OF LFA-3 ISIS PHARMACEUTICALS INC (US) 2003-06-11 EP disclosed
WO-2003031578-A2 MAMMALIAN C-TYPE LECTINS IMMUNEX CORPORATION (US) 2003-04-17 WO disclosed
EP-1086116-A1 COMPOSITIONS AND METHODS FOR THE PULMONARY DELIVERY OF NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 2001-03-28 EP disclosed
EP-1064402-A1 ANTISENSE MODULATION OF LFA-3 ISIS PHARMACEUTICALS, INC. (US) 2001-01-03 EP disclosed
EP-1064403-A1 ANTISENSE MODULATION OF PECAM-1 ISIS PHARMACEUTICALS, INC. (US) 2001-01-03 EP disclosed
EP-1003916-A1 ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS ISIS PHARMACEUTICALS, INC. (US) 2000-05-31 EP disclosed
WO-1999060010-A1 COMPOSITIONS AND METHODS FOR THE PULMONARY DELIVERY OF NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 1999-11-25 WO disclosed
WO-1999047707-A1 ANTISENSE MODULATION OF LFA-3 ISIS PHARMACEUTICALS, INC. (US) 1999-09-23 WO disclosed
WO-1999047708-A1 ANTISENSE MODULATION OF PECAM-1 ISIS PHARMACEUTICALS, INC. (US) 1999-09-23 WO disclosed
WO-1999011820-A1 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND QUANTITATION OF DELETION SEQUENCE OLIGONUCLEOTIDES IN SYNTHETIC OLIGONUCLEOTIDE PREPARATIONS ISIS PHARMACEUTICALS, INC. (US) 1999-03-11 WO disclosed
WO-1999009214-A1 ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS ISIS PHARMACEUTICALS, INC. (US) 1999-02-25 WO disclosed